SPOTLIGHT: OctoPlus reports positive hep C data


Amsterdam-based OctoPlus says that its hepatitis C drug Locteron demonstrated an antiviral effect in Phase IIa. OctoPlus is developing Locteron with Biolex, which is planning a Phase IIb trial for next year. Release

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.